ABOUT US Towards better quality of life, GNT Pharma

History

2021~
2021
  • 02.

    Crisdesalazine / GedaCure: Approved as a treatment for CCDS in South Korea – South Korea’s first synthetic new veterinary drug

  • 03.

    Nelonemdaz: U.S./PCT international patent application filed for use in the treatment of stroke with reperfusion

  • 05.

    GedaCure: GNT Pharma and Yuhan Corporation launch marketing in South Korea

  • 08.

    Nelonemdaz: IND approved in South Korea for phase III trial in stroke patients treated with endovascular thrombectomy (RODIN)

  • 11.

    Crisdeslazine: Initiation of Phase 1b testing in South Korea

  • 12.

    Flusalazine: Priority patent application filed with the US Patent and Trademark Office covering use in COPD and asthma

2020 ~ 2016
2020
  • 01.

    Crisdesalazine: Completion of Phase III SMART trial in dogs with CCDS

  • 02.

    Crisdesalazine: Product license application filed for marketing as Gedacure to treat CCDS

  • 03.

    Nelonemdaz: Completion of patient enrollment for Phase II SONIC stroke trial

  • 03.

    Nelonemdaz: U.S. Priority Patent Application filed for use in the treatment of stroke with reperfusion

  • 04.

    Nelonemdaz: Award granted from the Ministry of Health and Welfare to support Phase II AWAKE trial in cardiac arrest

  • 05.

    TFM: Completion of human clinical trials as a cosmetic treatment for wrinkles and skin hyperpigmentation

  • 10.

    Nelonemdaz: Completion of Phase II SONIC stroke trial in South Korea

  • 12.

    Nelonemdaz: Initiation of patient enrollment for Phase III ENIS stroke trial (ENIS) in China

2019
  • 01.

    Nelonemdaz: Completion of Phase II ENIS trial in stroke (238 people)

  • 01.

    Nelonemdaz: Initiation of Phase II AWAKE trial in cardiac arrest patients

  • 01.

    Crisdesalazine: U.S. Priority Patent application filed for use in CCDS

  • 01.

    Brain Science Park conference held

  • 02.

    Crisdesalazine: Approval granted in South Korea for Phase III trial in dogs with CCDS (SMART)

  • 07.

    Trifluoromethylphenethyl mesalazine (TFM) listed in the International Ingredient Dictionary and Handbook and patent application filed covering dermatological uses

  • 12.

    Nelonemdaz: Designated as an Orphan Drug in Development Stage by the Ministry of Food and Drug Safety of South Korea

  • 12.

    Dementia and stroke new drug clinical presentation held
    (Suwon Convention Center)

2018
  • 06.

    Nelonemdaz: Phase II trial in cardiac arrest (AWAKE) initiated

  • 07.

    Brain Science Park creation agreement signed

  • 08.

    Crisdesalazine: demonstrated cognitive benefit in dogs with canine cognitive dysfunction syndrome (CCDS)

  • 09.

    Brain science development forum held

  • 10.

    GNT Pharma won the Money Today “Bio Grand Prize”

  • 11.

    Crisdesalazine: Memorandum of understanding signed with Chinese partner Ledun Technology for marketing in China

2017
  • 05.

    Nelonemdaz: Approval granted by the KFDA in South Korea for Phase II study in patients resuscitated after out-of-hospital cardiac arrest (AWAKE)

  • 08.

    GNT Pharma and Apeloa Pharmaceuticals sponsored an international symposium focusing on stroke and possible use of nelonemdaz to treat stroke

2016
  • 01.

    Nelonemdaz: Patent application for compound and use filed in the E.U.

  • 01.

    Nelonemdaz: Submission of report on the results of the Phase 1 study in China; IND application submitted for Phase 2 clinical trial in acute stroke patients treated with medical thrombolysis (ENIS)

  • 02.

    The 1st GNT Pharma Forum for stroke held at the Catholic University of Korea, College of Medicine

  • 05.

    Nelonemdaz: Approval granted by the MFDS (Ministry of Food and Drug Safety) in South Korea for Phase II study in acute stroke patients treated with endovascular thrombectomy (SONIC)

  • 09.

    Nelonemdaz: Approval granted by the CFDA in China for Phase II study in stroke (ENIS)

  • 10.

    Acquisition of a new head office and R&D Center located in Yongin-si

2015 ~ 2011
2015
  • 01.

    GNT Pharma and Apeloa Pharmaceuticals selected by the China Science and Technology Innovation Team

  •  

    Nelonemdaz: Completion of Phase I study with 70 healthy subjects in China

  • 04.

    Nelonemdaz: Patent application filed in Japan for use in the treatment of burn injury

2014
  • 04.

    Crisdesalazine: Synthesis patent applications filed in the U.S. and Japan

  • 06.

    Nelonemdaz: Patent application filed in China for use in the treatment of burn injury

  • 10.

    Nelonemdaz: Approval granted in China for clinical trials

  • 11.

    Crisdesalazine: Patent application filed in the E.U. and Japan for use in the treatment of depression

2013
  • 06.

    Crisdesalazine: Synthesis patent application filed in China

  • 12.

    Flusalazine: Patent applications filed in the U.S., China, and Japan for use in the treatment of inflammatory diseases and pain

2012
  • 07.

    Nelonemdaz: Patent application filed in South Korea for use in the treatment of burn injury

  • 07.

    Crisdesalazine: Synthesis patent application filed in the EU

  • 07.

    Flusalazine: Patent application filed in South Korea for use in the treatment of inflammatory diseases

2011
  • 04.

    Nelonemdaz: KFDA approval granted for a Phase II study in acute stroke patients in South Korea

  • 07.

    Nelonemdaz: Submission and revision of IND and NDA to SFDA for clinical trials in China

  •  

    Crisdesalazine: Successful completion of Phase Ia study in South Korea

2010 ~ 2006
2010
  • Nelonemdaz: Patent application for the treatment of burn injury filed in Korea
  • Crisdesalazine: Compound patent application filed in the U.S., Japan, and China
  • Crisdesalazine: Initiation of Phase Ia study in South Korea
2009
  • Crisdesalazine: KFDA approval granted for a Phase Ia study in South Korea
  • Crisdesalazine: Compound and use patent application filed in Canada
  • Nelonemdaz: Patent application covering synergistic use with brain-derived neurotrophic factor filed in the U.S.
  • Flusalazine: Compound and use (treatment of pain and inflammatory diseases) patent application filed in South Korea
  • Nelonemdaz: Partnering and licensing deals with Jiayuan Pharmaceuticals for marketing in China
2008
  • Successful completion of nelonemdaz Phase I study in the U.S.
  • Nelonemdaz: Compound and use patent applications filed in Japan and the U.S.
2007
  • Flusalazine (ND-07) discovered as a drug candidate for the treatment of pain and inflammatory diseases
2006
  • Establishment of GNT’s business office at Gyeonggi Biocenter
  • Grant Award (National R&D Project Award) from the Ministry of Health & Welfare (2006-2009)
    Development of crisdesalazine for the Treatment of Alzheimer’s Disease
  • Grant Award (21C Brain Frontier Project) from MOST (2006-2009)
    Drug discovery for the Treatment of Neuropathic Pain
  • Nelonemdaz: Phase I study initiated in the U.S.
2005 ~ 2001
2005
  • Nelonemdaz: Completion of pre-clinical safety study
2004
  • Crisdesalazine (AAD-2004) discovered as a drug candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.
  • Grant Award (Driving Force Project for the Next Generation) from the Gyeonggi Provincial Government (2004-2009)
    Drug Discovery and Development for the Treatment of Spinal Cord Injury
2003
  • Nelonemdaz: Patent application for compound and use filed in South Korea
  • Grant Award (21C Brain Frontier Project) from MOST
    Drug discovery for Alzheimer’s disease (2003-2006)
  • Grant Award (21C Proteomics Frontier Project) from MOST
    Application of proteomics for prevention and treatment of ischemic brain injury
2001
  • Nelonemdaz: Completion of efficacy study in animal models of stroke
2000 ~ 1998
2000
  • Patent application for a multi-target brain cell protection drug library
1999
  • GNT Pharma designated as “Venture Business” by the Small and Medium Business Administration.
  • Grant Award (National Research Laboratory) from MOST (1999-2004)
    Study for the Interventional Therapy of Stroke and Alzheimer’s Disease
  • Grant Award (National Research Laboratory) from MOST (1999-2004)
    Eye Research Laboratory
1998
  • GNT Pharma was founded on April 3.
  • Grant Award (G7 Project) from the Ministry of Science & Technology (MOST)
    Development of animal models and therapeutic approaches for Alzheimer’s Disease (1998-2002)
  • Grant Award (Science Research Center) from MOST
    Brain Disease Research Center (1998-2007)